Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Genetics|March 20, 1998
Functional dissection of yeast Hir1p, a WD repeat-containing transcriptional corepressorH DeSilva, K Lee, M A Osley
Pharmaceutical Research|June 1, 1995
5-Bromomethyl fluorescein (5-BMF) for derivatization of carboxyl containing analytes for use with laser-induced fluorescence detectionP S Mukherjee, K H DeSilva, H T Karnes
Biomedical Chromatography : BMC|November 1, 1996
Pyrene sulphonyl chloride as a reagent for quantitation of oestrogens in human serum using HPLC with conventional and laser-induced fluorescence detectionK H DeSilva, F B Vest, H T Karnes
Molecular and Cellular Biology|February 1, 1997
Hir1p and Hir2p function as transcriptional corepressors to regulate histone gene transcription in the Saccharomyces cerevisiae cell cycleM S Spector, A Raff, H DeSilva, et al.
Thrombosis and Haemostasis|January 23, 1991
Characterization of a mouse factor IX cDNA and developmental regulation of the factor IX gene expression in liverS N Yao, A H DeSilva, S Kurachi, et al.
Anesthesia and Analgesia|July 1, 1995
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgeryP H Desilva, A H Darvish, S M McDonald, et al.
ESMO Open|December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trialT K Choueiri, T M Kuzel, S S Tykodi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialN M Tannir, L Albigès, D F McDermott, et al.
Pageof 1